about
Magnetic core-shell nanoparticles for drug delivery by nebulizationOptimized aerosol delivery to a mechanically ventilated rodent.Aerosol-mediated delivery of AAV2/6-IκBα attenuates lipopolysaccharide-induced acute lung injury in rats.Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications.Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.Early-stage development of novel cyclodextrin-siRNA nanocomplexes allows for successful postnebulization transfection of bronchial epithelial cells.Optimization and Dose Estimation of Aerosol Delivery to Non-Human Primates.Can high efficiency aerosol delivery continue after extubation?Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene Therapy Studies.Aerosol: a novel vehicle in pharmacotherapy in neonates.Chemical Design of Both a Glutathione-Sensitive Dimeric Drug Guest and a Glucose-Derived Nanocarrier Host to Achieve Enhanced Osteosarcoma Lung Metastatic Anticancer Selectivity.Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin.Comparison of Heterosubtypic Protection in Ferrets and Pigs Induced by a Single-Cycle Influenza Vaccine.Nebulised lipid-polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cellsComparison of aerosol delivery across combinations of drug delivery interfaces with and without concurrent high-flow nasal therapyInvestigation of the Quantity of Exhaled Aerosols Released into the Environment during NebulisationVibrating Mesh Nebulisation of Pro-Antimicrobial Peptides for Use in Cystic Fibrosis.The presence of inorganic calcium in pediatric parenteral admixturesNanotechnology based therapeutics for lung diseaseProgress in mucosal immunization for protection against pneumococcal pneumoniaThe effect of UV-protected ethylene vinyl acetate (EVA) bags on the physicochemical stability of pediatric parenteral nutrition admixturesInvestigation of Fugitive Aerosols Released into the Environment during High-Flow TherapyAerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques
P50
Q28393991-06FD53B2-136D-4821-B251-7A505B3AC077Q33439110-A18E4D3B-FE9B-40FF-A287-00BBF06B6E8CQ34999489-935195A0-E70D-4902-9075-BE0723DF238CQ37947952-9D82FE48-E970-4EC5-AE4D-01817E122E96Q38619090-BC08723E-0CEF-4C94-A62E-2D1677712FD1Q39012050-66D8A185-9093-415C-A742-0E57E1D24671Q41066514-B98466AB-956F-4EFC-8E9A-1E9E063983D0Q45827073-FA4E7D5E-4B4B-4351-A321-39A2A62F8CFCQ47552415-52F2A57D-B3C6-4F27-A9F9-D5D87C6E1C75Q47768987-37434D65-EDFF-4CBC-8FDF-FE0833CDE8FDQ48208676-5BBB34A8-B254-4805-88F2-3B84BE1B64DAQ51334028-F450D68A-42D1-4F1B-9FD3-F4BEFF2F7D86Q54226450-CF02573F-E284-4C71-B5B1-342FF579B98FQ64066569-82A51F97-4960-4ADC-9F8B-B805F80C285AQ64080578-DF770AA5-9227-42F6-9AAD-DCA8ABB6A336Q64250774-5DA9B772-9267-4112-B915-F37E3C55AF3CQ64986513-762EF9F9-D94C-4905-9745-02DCE45EC078Q88129827-D8817F6B-5A33-4E20-A3FC-045CD0624D53Q91721839-4BF3E7B3-753A-4C49-9083-1A444FB3686EQ91876394-8B02DF63-9F08-4517-B96F-D3C6C5C9F57DQ92127707-11E5C7DF-0A59-46DA-B493-F55DB0CD9873Q92494821-55753FD9-B04B-4D1F-BFBD-DB53E570385FQ92764604-2AAB7778-F092-4D4E-A8F5-0732FEBDA3BD
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3164-1607
@en
name
Ronan MacLoughlin
@ast
Ronan MacLoughlin
@en
Ronan MacLoughlin
@es
Ronan MacLoughlin
@nl
type
label
Ronan MacLoughlin
@ast
Ronan MacLoughlin
@en
Ronan MacLoughlin
@es
Ronan MacLoughlin
@nl
prefLabel
Ronan MacLoughlin
@ast
Ronan MacLoughlin
@en
Ronan MacLoughlin
@es
Ronan MacLoughlin
@nl
P106
P31
P496
0000-0002-3164-1607